Routine board appointment with no immediate trading catalyst. Monitor for any future strategic moves given Mr. Pauls' rare disease and M&A background, but no actionable signal from this filing alone.
Price Chart
Executive Summary
Palvella Therapeutics appointed Matthew Pauls as a Class I director, expanding the board from seven to eight members. Mr. Pauls is the CEO of Savara, Inc. and brings rare disease and commercialization experience, including a prior board role at Soleno Therapeutics through its $2.9B acquisition. This is a routine board appointment with no material financial impact.
Key Facts
- Board expanded from 7 to 8 members on June 29, 2026
- Matthew Pauls appointed as Class I director, term expiring at 2027 Annual Meeting
- Mr. Pauls is CEO of Savara, Inc. (NASDAQ: SVRA)
- Granted option to purchase 6,000 shares vesting monthly over 36 months
- No related party transactions or family relationships with existing directors/officers
- Board determined Mr. Pauls is independent under Nasdaq rules
Financial Impact
Standard non-employee director compensation — option for 6,000 shares with 36-month vesting; annual retainer per policy. Immaterial relative to $2.1B market cap.
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-079087 |
| Document: 0001104659-26-079087-index-headers.html | 0001104659-26-079087 |
| Document: 0001104659-26-079087-index.html | 0001104659-26-079087 |
| Document: 0001104659-26-079087.txt | 0001104659-26-079087 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access